Curis (NASDAQ:CRIS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Tuesday.
According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. “
A number of other equities research analysts have also recently weighed in on the stock. ValuEngine cut shares of Curis from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. Guggenheim initiated coverage on shares of Curis in a research report on Monday, October 23rd. They issued a “buy” rating and a $7.00 price target for the company. Three equities research analysts have rated the stock with a sell rating and three have given a buy rating to the stock. Curis presently has an average rating of “Hold” and an average target price of $6.50.
Curis (NASDAQ CRIS) remained flat at $$0.68 during trading on Tuesday. The company’s stock had a trading volume of 1,032,305 shares, compared to its average volume of 1,294,000. The firm has a market capitalization of $113.08, a PE ratio of -1.74 and a beta of 1.63. Curis has a 12-month low of $0.67 and a 12-month high of $3.22. The company has a debt-to-equity ratio of 1.24, a quick ratio of 5.15 and a current ratio of 5.15.
Curis (NASDAQ:CRIS) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.02). The firm had revenue of $2.44 million for the quarter, compared to analysts’ expectations of $2.19 million. Curis had a negative return on equity of 250.58% and a negative net margin of 629.29%. Curis’s revenue for the quarter was up 38.6% on a year-over-year basis. During the same period last year, the firm posted ($0.21) earnings per share. analysts anticipate that Curis will post -0.41 earnings per share for the current year.
In other Curis news, CEO Ali Ph.D. Fattaey bought 50,000 shares of Curis stock in a transaction dated Wednesday, November 15th. The stock was acquired at an average cost of $1.06 per share, with a total value of $53,000.00. Following the completion of the acquisition, the chief executive officer now owns 115,890 shares of the company’s stock, valued at $122,843.40. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.07% of the stock is owned by insiders.
Several large investors have recently made changes to their positions in the company. First Eagle Investment Management LLC raised its holdings in shares of Curis by 10.4% in the third quarter. First Eagle Investment Management LLC now owns 26,508,672 shares of the biotechnology company’s stock valued at $39,498,000 after buying an additional 2,500,000 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Curis by 2.6% in the second quarter. Vanguard Group Inc. now owns 4,955,068 shares of the biotechnology company’s stock valued at $9,365,000 after buying an additional 127,443 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Curis by 62,201.8% in the third quarter. JPMorgan Chase & Co. now owns 2,381,798 shares of the biotechnology company’s stock valued at $3,691,000 after buying an additional 2,377,975 shares during the last quarter. State Street Corp raised its holdings in shares of Curis by 10.4% in the second quarter. State Street Corp now owns 1,857,044 shares of the biotechnology company’s stock valued at $3,511,000 after buying an additional 175,424 shares during the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Curis by 3.8% in the second quarter. Northern Trust Corp now owns 1,334,679 shares of the biotechnology company’s stock valued at $2,523,000 after buying an additional 49,310 shares during the last quarter. 55.22% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Curis (CRIS) Cut to Sell at Zacks Investment Research” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/01/09/curis-cris-cut-to-sell-at-zacks-investment-research.html.
Curis Company Profile
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.